U.S. patent application number 16/992328 was filed with the patent office on 2020-11-26 for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof.
The applicant listed for this patent is Milestone Pharmaceuticals Inc.. Invention is credited to Martin P. MAGUIRE.
Application Number | 20200368195 16/992328 |
Document ID | / |
Family ID | 1000005016414 |
Filed Date | 2020-11-26 |
![](/patent/app/20200368195/US20200368195A1-20201126-C00001.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00002.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00003.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00004.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00005.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00006.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00007.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00008.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00009.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00010.png)
![](/patent/app/20200368195/US20200368195A1-20201126-C00011.png)
View All Diagrams
United States Patent
Application |
20200368195 |
Kind Code |
A1 |
MAGUIRE; Martin P. |
November 26, 2020 |
HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE
CALCIUM CHANNEL BLOCKER AND USES THEREOF
Abstract
The present invention includes surprisingly water-soluble salts
of a phenylalkylamine compound that are potent antagonists of
L-type calcium channels. Aqueous solutions including salts of the
instant invention are formulated for nasal administration and
provide a novel therapeutic platform for the treatment of stable
angina, migraine, and cardiac arrhythmia, such as paroxysmal
supraventricular tachycardia.
Inventors: |
MAGUIRE; Martin P.;
(Plattsburgh, NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Milestone Pharmaceuticals Inc. |
Saint-Laurent |
|
CA |
|
|
Family ID: |
1000005016414 |
Appl. No.: |
16/992328 |
Filed: |
August 13, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16721275 |
Dec 19, 2019 |
|
|
|
16992328 |
|
|
|
|
16414936 |
May 17, 2019 |
|
|
|
16721275 |
|
|
|
|
16144315 |
Sep 27, 2018 |
|
|
|
16414936 |
|
|
|
|
15566122 |
Oct 12, 2017 |
10117848 |
|
|
PCT/CA2016/050425 |
Apr 13, 2016 |
|
|
|
16144315 |
|
|
|
|
62147427 |
Apr 14, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/08 20130101; A61K
31/277 20130101; A61K 47/02 20130101; A61P 9/10 20180101; A61P
25/06 20180101; A61P 9/06 20180101; A61K 47/20 20130101; A61K 47/10
20130101; A61K 47/12 20130101; C07C 255/42 20130101; A61K 9/0043
20130101; A61K 47/26 20130101; A61K 47/183 20130101 |
International
Class: |
A61K 31/277 20060101
A61K031/277; A61K 9/08 20060101 A61K009/08; C07C 255/42 20060101
C07C255/42; A61K 9/00 20060101 A61K009/00; A61K 47/12 20060101
A61K047/12; A61K 47/18 20060101 A61K047/18; A61K 47/20 20060101
A61K047/20; A61P 9/10 20060101 A61P009/10; A61P 9/06 20060101
A61P009/06; A61P 25/06 20060101 A61P025/06; A61K 47/02 20060101
A61K047/02; A61K 47/10 20060101 A61K047/10; A61K 47/26 20060101
A61K047/26 |
Claims
1. An aqueous composition formulated for nasal administration
comprising a pharmaceutically acceptable salt or free base of a
compound selected from the group consisting of ##STR00016##
verapamil, gallopamil, and devapamil, or a racemate or enantiomer
thereof, wherein the compound is dissolved in the aqueous
composition at a concentration of between 150 mg/mL and 600
mg/mL.
2. The aqueous composition of claim 1, wherein the compound is
compound 1.
3. The aqueous composition of claim 2, wherein the compound is the
S-enantiomer of compound 1.
4. The aqueous composition of anyone of claims 1-3, wherein the
concentration is approximately 350 mg/mL.
5. The aqueous composition of any one of claims 1-3, wherein the
concentration is approximately 450 mg/mL.
6. The aqueous composition of any one of claims 1-3, wherein the
aqueous composition comprises from 40% to 85% (w/v) water.
7. The aqueous composition of any one of claims 1-3, wherein the
aqueous composition has a pH of 4.5.+-.1.5.
8. The composition of any one of claims 1-7, wherein the aqueous
composition comprises a compound selected from the group consisting
of compound I, verapamil, gallopamil, and devapamil and between 0.5
and 1.5 molar equivalents of acetic acid relative to the
compound.
9. The composition of any one of claims 1-7, wherein the aqueous
composition comprises a compound selected from the group consisting
of compound I, verapamil, gallopamil, and devapamil and between 0.5
and 1.5 molar equivalents of methanesulfonic acid relative to the
compound.
10. The aqueous composition of any one of claims 1-9, wherein the
composition further comprises a chelating agent.
11. The composition of claim 10, wherein the chelating agent is an
aminopolycarboxylic acid.
12. The composition of claim any one of claims 1-11, wherein the
aqueous composition further comprises EDTA.
13. The composition of any one of claims 1-12, wherein the
composition further comprises a pH adjusting agent selected from
the group consisting of sulfuric acid and methanesulfonic acid.
14. The composition of claim 13, wherein the pH adjusting agent is
sulfuric acid.
15. The composition of any one of claims 1-14, wherein the
composition exhibits a viscosity of between 10 mPa*s and 70
mPa*s.
16. The composition of any one of claims 1-15, wherein the
composition further comprises a pharmaceutically acceptable
excipient.
17. The composition of claim 16, wherein the excipient is
polysorbate or propylene glycol.
18. The composition of any one of claims 1-17, wherein the aqueous
solution comprising the salt of a compound selected from the group
consisting of compound I, verapamil, gallopamil, and devapamil
remains homogeneous at room temperature.
19. The composition of any one of claims 1-17, wherein the aqueous
solution comprising the salt of a compound selected from the group
consisting of compound I, verapamil, gallopamil, ad devapamil
remains homogeneous at 10.degree. C. for 4 days.
20. The composition of any one of claims 1-17, wherein the aqueous
solution comprising the salt of a compound selected from the group
consisting of compound I, verapamil, gallopamil, and devapamil
remains homogeneous at 2-5.degree. C. for 7 days.
21. A nasal delivery system comprising a composition of any one of
claims 1-20 in a unit dosage form comprising no more than four
single pump spray dosages.
22. A nasal delivery system comprising a composition or any one of
claims 1-20 in a unit dosage form comprising no more than two
single pump spray dosages.
23. The nasal delivery system of claim 21 or 22, wherein the unit
dosage form is configured for administration of no more than 200
microliters of the composition to each nostril of a patient.
24. The nasal delivery system of claim 21 or 22, wherein the unit
dosage form is configured for administration of no more than 150
microliters of the composition to each nostril of a patient.
25. A composition comprising the acetate salt of a compound
selected from the group consisting of compound I, verapamil,
gallopamil, and devapamil.
26. A composition comprising the methanesulfonate salt of a
compound selected from the group consisting of compound I,
verapamil, gallopamil, and devapamil.
27. A method of treating a disease selected from the group
consisting of cardiac arrhythmia, stable angina, and migraine, said
method comprising nasally administering to a patient in need
thereof an aqueous composition comprising a pharmaceutically
acceptable salt of a compound selected from the group consisting of
compound I, verapamil, gallopamil, and devapamil, wherein the
compound is dissolved in the aqueous composition at a concentration
of between 150 mg/mL and 600 mg/mL.
28. The method of claim 27, wherein said disease is cardiac
arrhythmia.
29. The method of claim 27, wherein said disease is stable
angina.
30. The method of claim 27, wherein said disease is migraine.
31. The method of claim 28, wherein said cardiac arrhythmia is
PSVT, atrial fibrillation, or ventricular tachycardia.
32. The method of anyone or claims 27-31, wherein the compound
reaches a therapeutically effective concentration in plasma of the
patient within 3 to 5 minutes of administration to the patient.
33. The method of any one of claims 27-32, the method comprising
administering between 150 microliters and 200 microliters of the
aqueous composition to the patient.
34. The method of any one of claims 27-33, wherein the patient is a
human.
35. Use of the composition of any one of claims 1-20 in the
manufacture of a medicament for the treatment of a disease selected
from the group consisting of cardiac arrhythmia, stable angina, and
migraine.
36. The use according to claim 35, wherein said disease is cardiac
arrhythmia.
37. The use according to claim 35, wherein said disease is stable
angina.
38. The use according to claim 35, wherein said disease is
migraine.
39. The use according to claim 36, wherein said cardiac arrhythmia
is PSVT, atrial fibrillation, or ventricular tachycardia.
40. A method of making a solution formulated for nasal
administration to a patient, the method comprising the steps of a.
adding a solution comprising a first dissolved acid to the free
base of a compound of claim 1 to form a mixture; b. adding to the
mixture a solution comprising ethylenediaminetetracetic acid; c.
heating and mechanically stirring the resulting mixture until the
compound has fully dispersed within the mixture; d. adjusting the
pH of the mixture by adding a solution comprising a second
dissolved acid to the mixture; and e. diluting the mixture such
that the final concentration of the compound in solution is at
least 300 mg per 1 milliliter.
41. The method of claim 40, wherein the first dissolved acid is
selected from the group consisting of acetic acid and
methanesulfonic acid.
42. The method of claim 40, wherein the second dissolved acid is
selected from the group consisting of acetic acid, sulfuric acid,
and methanesulfonic acid.
43. The method of claim 40, wherein the final pH of the solution is
between about 4.0 and about 5.0.
44. The method of claim 43, wherein the final pH of the solution is
about 4.5.
45. The method of claim 40, wherein the solution comprising the
salt of the compound remains homogeneous at 10.degree. C. for 4
days.
46. The method of claim 40, wherein the solution comprising the
salt of the compound remains homogeneous at 2-5.degree. C. for 7
days.
Description
BACKGROUND OF THE INVENTION
[0001] The invention relates to salts including a phenylalkylamine
compound that exhibit surprisingly high solubility in aqueous
solution. The salts of the instant invention are validated
antagonists of L-type calcium channels and provide a new
therapeutic platform for the treatment of cardiac arrhythmias, such
as paroxysmal supraventricular tachycardia, stable angina, and
migraines.
Cardiac Arrhythmia
[0002] Cardiac arrhythmia, or abnormal heart rhythm, is caused by
abnormal excitation and conduction to the heart. A normal heartbeat
is regulated by the sinoatrial (SA) node, a collection of cells
embedded within the right atrium proximal to the superior vena
cava. Under healthy physiological conditions, the SA node
spontaneously initiates action potentials at regular intervals and
propagates these electrochemical signals from the right atrium to
the left atrium. Each coordinated pulse induces an influx of
calcium ions (Ca.sup.2+) into the cardiomyocyte fibers of the SA
node through voltage-gated calcium channels, which ultimately
enables the cardiac muscle tissue to contract and expel blood from
the atria into the ventricles. This signal is subsequently
propagated to the atrioventricular (AV) node, which propagates the
action potential to the right and left ventricles. This signal
triggers an influx of extracellular calcium, which in turn
facilitates contraction of ventricular cardiomyocytes and the
expulsion of blood from the heart and into circulation.
[0003] The precise coordination of these events is vital to
maintaining a regular heartbeat, and the aberrant activity of this
electrochemical conduction system gives rise to arrhythmia. A
recurrent arrhythmia with an abrupt onset and termination is
designated as paroxysmal. Symptoms of paroxysmal supraventricular
tachycardia (PSVT) include episodes of regular and paroxysmal
palpitations with sudden onset and termination (Blomstrom-Lundqvist
et al., J. Am. Coll. Cardiol., 2003, 42:1493-531). The signaling
mechanisms that underlie PSVT include the initiation and
propagation of action potentials along accessory nodes that cause
abnormal cardiomyocyte contractions that interfere with the
coordinated atrial-to-ventricular blood flow. The most common form
of PSVT is AV nodal reentrant tachycardia (AVNRT), a disorder
characterized by the development of conducting tissue proximal to
the AV node. This tissue forms a closed loop known as a reentry
circuit, which enables action potentials to be propagated
circularly throughout the heart rather than in a linear fashion. As
a result, patients experience rapid palpitations and severely
elevated heart rates. Episodes of tachycardia are often accompanied
by a drop in blood pressure, which can induce dizziness or
fainting. It is estimated that PSVT affects greater than 1.7
million treatable patients in the United States, and over 89,000
new cases are reported annually. Strikingly, many of these patients
do not exhibit other signs of cardiovascular disease. Episodes of
PSVT can be induced by various factors, including physical and
psychological stress, infection, anemia, menstruation, and
pregnancy (Lee, et al., Curr. Probl. Cardiol., 2008,
33:467-546).
Current Modes of Treatment
[0004] There are currently several therapeutic modalities available
to PSVT patients. However, these platforms generally suffer from
several deficiencies, chief among them being invasiveness or
inefficiency. Patients can frequent the emergency room for
immediate intervention during an episode, but this strategy
provides only temporary relief. Such patients may continue to
experience episodes of tachycardia throughout their lifetimes.
Patients who suffer from chronic episodes of PSVT can have the
nodal fibers that propagate anomalous action potentials ablated in
order to permanently disrupt the mechanism that underlies the
irregular cardiomyocyte contractions. This procedure typically
requires that a catheter tube be inserted into the patient's throat
in order to access the heart, where a low-voltage pulse of
electricity is delivered to the aberrant signaling tissue. This
process is highly invasive, and patients are often fearful of
undergoing this form of treatment.
[0005] Alternatively, patients who suffer from chronic PSVT can
take oral medication to help attenuate the severity or reduce the
frequency of arrhythmia episodes. Calcium channel blockers
represent a class of compounds that is functionally well-suited to
ameliorate the symptoms of tachycardia, as these compounds are
capable of reducing the influx of extracellular calcium into
cardiomyocytes that ultimately leads to muscle contraction.
Prevalent examples of calcium channel antagonists include verapamil
and diltiazem, both of which are potent inhibitors of calcium
influx and are widely used to treat PSVT. However, despite the
widespread use of these therapeutics, patients who take these
medications may continue to experience episodes of tachycardia.
[0006] There currently is no commercially available therapeutic
product that can be self-administered during an episode of PSVT in
order to alleviate the symptoms during the episode. While calcium
channel blockers provide a validated strategy for terminating such
episodes, the development of such a product is a challenge due to
the precise pharmacokinetic profile necessary to rapidly alleviate
the symptoms without potentiating off target-mediated toxicity. A
desirable therapeutic must have the capacity for rapid infusion
into the bloodstream of a patient in a therapeutically effective
quantity and thus promptly terminate an episode of PSVT. The drug
must be subsequently metabolized and inactivated in rapid fashion
for a normal resting heart rate to be established. Current calcium
channel blocker formulations are designed for oral administration.
The passage of these compounds into the gastrointestinal tract and
the ensuing metabolism that occurs hinders the rapid entry of these
drugs into the bloodstream and renders the ideal pharmacokinetic
profile inaccessible. Instead, these drugs are released on a slower
time scale via absorption through the intestinal epithelium, which
delays their access to faulty cardiac muscle tissue.
[0007] The invention disclosed herein provides an innovative
strategy for treating cardiac arrhythmias, such as PSVT. The
instant invention includes a novel formulation of a calcium channel
blocker that enables the rapid delivery of the active compound into
the bloodstream so as to reach maximum concentrations in plasma of
PSVT patients within minutes of administration. This facilitates
the rapid termination of PSVT episodes. The formulation provides an
additional benefit in that the active calcium channel blocker is
subsequently metabolized and inactivated rapidly after reaching
maximal plasma concentrations. This pharmacokinetic profile is
ideal for a drug that can treat PSVT immediately during an episode.
The formulation of the present invention thus represents a new
therapeutic paradigm for targeting faulty cardiac signaling in a
precise and rapid fashion.
SUMMARY OF THE INVENTION
[0008] The present invention relates to the use of an aqueous
solution that contains a pharmaceutically effective amount of a
salt of a calcium channel antagonist for use in treating stable
angina, migraine, and cardiac arrhythmia, such as PSVT. The salts
of the instant invention are formulated for nasal administration,
which represents an administration route that has not previously
been exploited for treating PSVT. One of the challenges associated
with nasal administration is the volumetric limit imposed by the
nasal cavity. Administration of nasal sprays is typically limited
to approximately 150 to 200 .mu.L, beyond which point the liquid
solution begins to enter the throat. This, in turn, imposes a limit
on the quantity of a pharmaceutically active agent that can be
delivered to the epithelial lining of the nasal cavity. The salts
of the instant invention exhibit a surprisingly high solubility in
aqueous solution, which enables the development of concentrated
liquid solutions that can deliver therapeutically effective
quantities of the active agent to the nasal epithelium. Nasal
administration of the active agent is beneficial for achieving an
ideal pharmacokinetic profile, as the ability of the therapeutic
compound to traverse the nasal mucosa and rapidly enter the
bloodstream renders the drug capable of quickly targeting faulty
signaling in muscle tissue. The novel formulations described herein
represent a new therapeutic regimen for alleviating the symptoms of
stable angina, migraine, and cardiac arrhythmia, such as PSVT,
during an episode.
[0009] Embodiments of the invention include an aqueous composition
formulated for nasal administration containing a pharmaceutically
acceptable salt or free base of a compound selected from the group
consisting of a compound of the formula
##STR00001##
[0010] verapamil
(2-(3,4-dimethoxyphenyl)-S-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-p-
ropan-2-ylpentanenrtrile), represented by the formula
##STR00002##
[0011] gallopamil
(5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trim-
ethoxyphenyl)pentanenitrile), represented by the formula
##STR00003##
[0012] and devapamil
(2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-((m-methoxyphenethyl)methylamino)v-
aleronitrile), represented by the formula
##STR00004##
[0013] or a racemate or enantiomer thereof, wherein the compound is
dissolved in the aqueous composition at a concentration of between
150 mg/mL and 600 mg/mL.
[0014] In certain embodiments, the compound that is dissolved in
the aqueous composition is compound I. In preferred embodiments,
the compound that is dissolved in the aqueous composition is the
S-enantiomer of compound I.
[0015] Embodiments of the present invention include an aqueous
composition formulated for nasal administration containing a
pharmaceutically acceptable salt or free base of a compound
selected from the group consisting of
##STR00005## ##STR00006## ##STR00007## ##STR00008## ##STR00009##
##STR00010##
[0016] or a racemate or enantiomer thereof, wherein the compound is
dissolved in the aqueous composition at a concentration of between
150 mg/mL and 600 mg/mL.
[0017] Embodiments of the present invention also include an aqueous
composition formulated for nasal administration containing a
pharmaceutically acceptable salt or free base of a compound
selected from the group consisting of
##STR00011## ##STR00012##
[0018] or a racemate or enantiomer thereof, wherein the compound is
dissolved in the aqueous composition at a concentration of between
150 mg/mL and 600 mg/mL.
[0019] In particular embodiments, the concentration of the compound
that is dissolved in the aqueous solution is approximately 350
mg/mL. In alternative embodiments, the concentration of the
compound that is dissolved in the aqueous solution is approximately
450 mg/mL. In certain cases, the aqueous composition of the instant
invention includes from 40% to 85% (w/v) water. In additional
embodiments of the invention, the aqueous composition has a pH of
4.5.+-.1.5.
[0020] Embodiments of the present invention include the aqueous
composition of any of the above embodiments, wherein the aqueous
composition contains a compound described herein, e.g., compound I,
verapamil, gallopamil, or devapamil and between 0.5 and 1.5 molar
equivalents of acetic acid relative to the compound. Alternative
embodiments of the present invention include the aqueous
composition of any of the above embodiments, wherein the aqueous
composition contains a compound described herein, e.g., compound I,
verapamil, gallopamil, or devapamil and between 0.5 and 1.5 molar
equivalents of methanesulfonic acid relative to the compound.
[0021] In certain cases, the invention includes the composition of
any of the above embodiments, wherein the composition contains a
chelating agent. In certain embodiments, the chelating agent is an
aminopolycarboxylic acid.
[0022] Additional embodiments of the invention include the
composition of any of the above embodiments, wherein the aqueous
composition contains ethylenediaminetetracetic acid (EDTA).
[0023] In other embodiments of the instant invention, the
composition of any of the above embodiments includes a pH adjusting
agent selected from the group consisting of sulfuric acid and
methanesulfonic acid. In preferred embodiments, the pH adjusting
agent is sulfuric acid.
[0024] Additional embodiments of the invention include the
composition of any of the above embodiments, wherein the
composition exhibits a viscosity of between 10 mPa*s and 70
mPa*s.
[0025] Additional aspects of the invention include the composition
of any one of the above embodiments, wherein the composition
includes a pharmaceutically acceptable excipient. In particular
embodiments of the invention, the excipient is selected from the
group consisting of polysorbate and propylene glycol.
[0026] Embodiments of the invention also include the composition of
any of the above embodiments, wherein the aqueous solution
containing the salt of a compound described herein, e.g., compound
I, verapamil, gallopamil, or devapamil remains homogenous at room
temperature.
[0027] In certain cases, the aqueous solution containing the salt
of a compound described herein, e.g., compound 1, verapamil,
gallopamil, or devapamil remains homogeneous at 10.degree. C. for 4
days. In other cases, the aqueous solution containing the salt of
compound I remains homogeneous at 2-5.degree. C. for 7 days.
[0028] The present invention also includes a nasal delivery system
containing a composition of any one of the above embodiments in a
unit dosage form that contains no more than four single pump spray
dosages. In alternative embodiments, the nasal delivery system
contains the composition of any of the above embodiments in a unit
dosage form that contains no more than two single pump spray
dosages.
[0029] In other embodiments of the invention, the unit dosage form
of the nasal delivery system is configured for administration of no
more than 200 microliters of the composition to each nostril of a
patient. In alternative forms of the invention, the unit dosage
form of the nasal delivery system is configured for administration
of no more than 150 microliters of the composition to each nostril
of a patient.
[0030] Embodiments of the present invention additionally include a
composition that contains the acetate salt of a compound described
herein, e.g., compound I, verapamil, gallopamil, or devapamil. In
alternative embodiments, the invention includes a composition that
contains the methanesulfonate salt of a compound described herein,
e.g., compound I, verapamil, gallopamil, or devapamil.
[0031] Alternative embodiments of the invention include a method
for enhancing permeability through the nasal epithelium of an
aqueous solution that contains the acetate salt or methanesulfonate
salt of a compound described herein, e.g., compound I, verapamil,
gallopamil, or devapamil formulated as a nasal spray solution,
wherein the concentration of the salt of a compound described
herein, e.g., compound I, verapamil, gallopamil, or devapamil is
between 150 and 600 mg/mL and the pH of the solution is 4.5.+-.1.5,
the method including about 5 mM EDTA in the nasal spray
solution.
[0032] Additional embodiments of the invention include a method of
treating a disease selected from the group consisting of cardiac
arrhythmia, stable angina, and migraine, the method including
nasally administering to a patient in need thereof an aqueous
composition that contains a pharmaceutically acceptable salt of a
compound described herein, e.g., compound I. verapamil, gallopamil,
or devapamil, wherein the compound is dissolved in the aqueous
composition at a concentration of between 150 mg/mL and 600 mg/mL.
In certain embodiments, the disease is cardiac arrhythmia. In other
embodiments, the disease is stable angina. In alternative
embodiment %, the disease is migraine. In particular embodiments,
the cardiac arrhythmia is PSVT, atrial fibrillation, or ventricular
tachycardia.
[0033] Embodiments of the invention include the method of any of
the above embodiments, wherein the compound reaches a
therapeutically effective concentration in plasma of the patient
within 3 to 5 minutes of administration to the patient.
[0034] Embodiments of the invention also include the method of any
of the above embodiments that further includes administering
between 150 microliters and 200 microliters of the aqueous
composition to the patient.
[0035] Preferred embodiments of the invention include the method of
any of the above embodiments, wherein the patient is a human.
[0036] Additional embodiments of the invention include the use of
the composition of any one of the above embodiments in the
manufacture of a medicament for the treatment of a disease selected
from the group consisting of cardiac arrhythmia, stable angina, and
migraine. In certain embodiments, the disease is cardiac
arrhythmia. In other embodiments, the disease is stable angina. In
alternative embodiments, the disease is migraine. In particular
embodiments, the cardiac arrhythmia is PSVT, atrial fibrillation,
or ventricular tachycardia.
[0037] The invention also includes a method of making a solution
formulated for nasal administration to a patient, wherein the
method includes the steps of [0038] a. adding a solution containing
a first dissolved acid to the free base of the compound of any of
the above embodiments to form a mixture; [0039] b. adding to the
mixture a solution that contains ethylenediaminetetracetic acid;
[0040] c. heating and mechanically stirring the resulting mixture
until the compound has fully dispersed within the mixture; [0041]
d. adjusting the pH of the mixture by adding a solution containing
a second dissolved acid to the mixture; and [0042] e. diluting the
mixture such that the final concentration of the compound in
solution is at least 300 mg per 1 milliliter.
[0043] In certain embodiments of the invention, the first dissolved
acid is selected from the group consisting of acetic acid and
methanesulfonic acid.
[0044] In particular embodiments, the second dissolved acid is
selected from the group consisting of acetic acid, sulfuric acid,
and methanesulfonic acid.
[0045] In additional embodiments, the final pH of the solution is
between about 4.0 and about 5.0. In preferred embodiments, the
final pH of the solution is about 4.5.
[0046] Embodiments of the invention also include the
above-described method, wherein the solution that contains the salt
of a compound described herein, e.g., compound 1, verapamil,
gallopamil, or devapamil remains homogenous at 10.degree. C. for 4
days. In alternative embodiments, the solution that contains the
salt of a compound described herein, e.g., compound I, verapamil,
gallopamil, or devapamil remains homogeneous at 2-5.degree. C. for
7 days.
Definitions
[0047] The term "tachycardia" as used herein refers to a resting
heart rate that is elevated relative to a normal state.
[0048] "Cardiac arrhythmia" as used herein refers to a condition
characterized by abnormal heart rhythms that are irregular, too
fast, too slow, or conducted via an abnormal electrical pathway
through the heart. Cardiac arrhythmias include atrial fibrillation
that is characterized by abnormally fast electrical discharge
patterns that cause the atria to contract very rapidly thereby
impairing efficient pumping of the blood into the ventricles.
Cardiac arrhythmias also include PSVT that is characterized by a
regular and fast heart rate originating in heart tissue above the
ventricles. Cardiac arrhythmias also include ventricular
tachycardia that is characterized by a rapid heartbeat that
originates in the lower chambers of the heart.
[0049] The term "angina" as used herein refers to chest discomfort
experienced due to ischemic heart disease. "Stable angina" is
angina that is principally caused by arteriosclerosis.
[0050] The term "migraine" as used herein is a disease
characterized by a recurrent headache that typically affects one
side of the head and is often accompanied by nausea, vomiting, or
sensitivity to light.
[0051] The term "excipient" is used herein to describe any
ingredient other than an active compound (e.g., one having Formula
I) described herein. Excipients may include, for example:
antiadherents, antioxidants, binders, coatings, compression aids,
disintegrants, dyes (colors), emollients, emulsifiers, fillers
(diluents), film formers or coatings, flavors, fragrances, glidants
(flow enhancers), lubricants, preservatives, printing inks,
sorbents, suspensing or dispersing agents, sweeteners, or waters of
hydration. Exemplary excipients include, but are not limited to:
butylated hydroxytoluene (BHT), calcium carbonate, calcium
phosphate (dibasic), calcium stearate, croscarmellose, crosslinked
polyvinyl pyrrolidone, citric acid, crospovidone, cysteine,
ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, lactose, magnesium stearate, maltitol, mannitol,
methionine, methylcellulose, methyl paraben, microcrystalline
cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone,
pregelatinized starch, propyl paraben, retinyl palmitate, shellac,
silicon dioxide, sodium carboxymethyl cellulose, sodium citrate,
sodium starch glycolate, sorbitol, starch (corn), stearic acid,
stearic acid, sucrose, tale, titanium dioxide, vitamin A, vitamin
E, vitamin C, and xylitol. Additional excipients may include,
without limitation, polysorbate, propylene glycol, hydroxypropyl
p-cyclodextrin, triethylcitrate, benzalkonium chloride, and
N-dodecyl-p-D-maltoside.
[0052] As used herein, a "chelating agent" is a molecule capable of
forming at least two chemical bonds with a metal cation so as to
form a complex.
[0053] As used herein, an "aminopolycarboxylic acid" is a molecule
that includes at least one amine and at least two carboxylic acid
functional groups. The carboxylic acids of an aminopolycarboxylic
acid may be deprotonated and exist in anionic form as carboxylate
groups. Examples of aminopolycarboxylic acids include, without
limitation, iminodiacetic acid (IDA), nitrilotriacetic acid (NTA),
pentetic acid (DTPA), ethylenediaminetetracetic acid (EDTA),
ethylene glycol tetraacetic acid (EGTA),
(1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) (BAPTA),
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
and
N--(N-(3-amino-3-carboxypropyl)-3-amino-3-carboxypropyl)azetidine-2-c-
arboxylic acid (nicotianamine), among others.
[0054] As used herein, the term "nasal administration" means
absorption of a compound or a pharmaceutically acceptable
formulation of a compound by contacting the compound or formulation
with the nasal epithelium. This can be achieved by spraying the
compound or formulation into the nasal cavity. Desirably the
compound is compound I, verapamil, gallopamil, or devapamil.
[0055] As used herein, a "pharmaceutically acceptable salt" or
"pharmaceutically acceptable acid addition salt" of a basic
pharmaceutically active compound is derived from the treatment of
the compound with an organic acid or an inorganic acid. Exemplary
pharmaceutically acceptable acid addition salts include those
derived from treatment of the compound with acetic acid or
methanesulfonic acid.
[0056] A "pharmaceutically acceptable carrier" As used herein,
refers to a vehicle capable of suspending or dissolving the active
compound, and having the properties of being nontoxic and
non-inflammatory in a patient. Moreover, a pharmaceutically
acceptable carrier may include a pharmaceutically acceptable
additive, such as a preservative, antioxidant, fragrance,
emulsifier, dye, or excipient known or used in the field of drug
formulation and that does not significantly interfere with the
therapeutic effectiveness of the biological activity of the active
agent, and that is non-toxic to the patient.
[0057] The term "pharmaceutically acceptable formulation" As used
herein, refers to a composition including a pharmaceutically
acceptable carrier and an active compound, e.g., the compound of
Formula I.
[0058] As used herein, the term "therapeutically effective amount"
refers to an amount of an active compound that, when administered
to a patient, reduces, eliminates, or prevents one or more symptoms
of a cardiac arrhythmia (such as PSVT), stable angina, or migraine.
Desirably, a therapeutically effective amount of a pharmaceutical
formulation is an aqueous solution that contains a compound of the
invention (e.g., a compound having Formula I) in a concentration
range of about 150 mg/mL to about 600 mg/mL.
[0059] These definitions and others stated in The Merck Manual
16.sup.th edition 1992 (Chapter 25. pp 461-498; Chapter 25, pp
498-507; and Chapter 24, pp 413-429) and Goodman and Gilman's "The
Pharmacological Basis of Therapeutics" 11.sup.th edition 2006
(Chapter 34, pp 899-908; Chapter 31, pp 823-824 and pp 830-832; and
Chapter 32, pp 845-846) are herein incorporated by reference.
[0060] Other features and advantages of the invention will be
apparent from the following Detailed Description and the
Claims.
DETAILED DESCRIPTION
[0061] The present invention was derived from the surprising
discovery that a previously characterized calcium channel blocker
could be formulated as an acid addition salt derived from acetic
acid or methanesulfonic acid so as to exhibit very high solubility
in aqueous solution. The compounds of the instant invention include
methyl
3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)-
benzoate, shown below in Formula I.
##STR00013##
Additional compounds of the invention include other calcium channel
blockers, such as verapamil, gallopamil, devapamil, and the
particular compounds described herein.
[0062] Previously known formulations of calcium channel blockers,
such as verapamil and diltiazem, do not provide immediate relief
from cardiac arrhythmia, stable angina, or migraine. This is due in
part to the pharmacokinetic profile of these drugs as formulated.
As oral therapeutics, these compounds enter the body via
gastrointestinal tract, where they are subject to acid-mediated or
enzyme-catalyzed degradation and inactivation. These compounds
slowly enter the bloodstream via absorption by the intestinal
epithelium. To date, this route of administration has hindered the
ability of these drugs to rapidly antagonize voltage-gated calcium
channels at the site of deviant cardiac signaling that underlies
cardiac arrhythmia, such as PSVT. As such, these drugs are commonly
taken as a chronic preventative treatment regimen and are not used
for the immediate relief of the symptoms of an episode of these
diseases. Moreover, as calcium signaling also modulates normal
cardiac muscle contractions, the ideal drug for treatment of an
episode of cardiac arrhythmia, such as PSVT, will be absorbed
quickly and subsequently metabolized and deactivated rapidly so as
to mitigate off-target calcium channel inhibition. Indeed, common
side effects of oral formulations of verapamil and diltiazem
include attenuated cardiomyocyte contractility and depressed AV
node conduction.
Water Soluble Aqueous Salts
[0063] Compound I and other calcium channel blockers, such as
verapamil, gallopamil, and devapamil, as well as enantiomers and
racemates of these compounds, may be dissolved in aqueous solution
and formulated for nasal administration. Nasal administration
offers an advantage over oral administration in that the
pharmaceutically active agent can rapidly traverse the nasal
epithelium and immediately enter the bloodstream. In this way, once
a therapeutically effective amount of the active compound is in the
bloodstream, the compound can disrupt aberrant cardiac signaling in
the anomalous cardiac fibers and provide a patient with relief from
an episode of cardiac arrhythmia, stable angina, or migraine once
it has started. After persisting in the blood for a time sufficient
to restore proper cardiomyocyte activity, the compound is
metabolized and deactivated in rapid fashion, so as to prevent
prolonged cardiac exposure and harmful side effects.
[0064] Despite the validated mechanisms of action of compound I,
verapamil, gallopamil, and devapamil, nasal administration requires
a high concentration of an active compound due to the volumetric
limit imposed by the nasal cavity. Administration of nasal sprays
is typically limited to approximately 150 to 200 .mu.L, beyond
which point the liquid solution begins to enter the throat. This,
in turn, imposes a limit on the quantity of a pharmaceutically
active agent that can be delivered to the epithelial lining of the
nasal cavity.
[0065] In light of the prevalence of aromatic and saturated
aliphatic moictics coupled with the lack of ionic or hydrogen
bond-donating functionality, it was not expected that compound I,
verapamil, gallopamil, or devapamil would be readily soluble in
aqueous solution. Moreover, given that a solution of one of these
compounds must be highly concentrated so as to enable the delivery
of a therapeutically effective quantity of the drug within the
volume limit imposed by the nasal cavity, prior to the present
invention, it was unknown whether this could be achieved.
[0066] Surprisingly, concentrated aqueous solutions of compound I
could be made by treating this compound with particular organic
acids in order to produce acid addition salts. Methanesulfonic acid
and acetic acid were capable of forming a salt solution with
compound I with concentrations sufficient for nasal administration.
For nasal administration, a desirable aqueous solution of compound
I will exhibit a solubility of between approximately 150 mg/mL and
600 mg/mL (e.g., 150+25 mg/mL, 175.+-.25 mg/mL, 200.+-.25 mg/mL,
225.+-.25 mg/mL, 250.+-.25 mg/mL, 275.+-.25 mg/mL, 300.+-.25 mg/mL,
325.+-.25 mg/mL, 350.+-.25 mg/mL, 375.+-.25 mg/mL, 400.+-.25 mg/mL,
425.+-.25 mg/mL, 450.+-.25 mg/mL, 475.+-.25 mg/mL, 500.+-.25 mg/mL,
525.+-.25 mg/mL, 550.+-.25 mg/mL, 575.+-.25 mg/mL, or 600.+-.25
mg/mL). These concentrations correspond to a percentage of water of
between 40% and 85% (w/v). Surprisingly, it was discovered that
acetic acid and methanesulfonic acid were indeed capable of
individually producing salts of compound I with high solubility in
aqueous solution. The high solubility of the acetate and mesylate
salts of compound I renders these salts uniquely suited for nasal
administration, as the high concentrations of compound I attainable
in these salt forms enable the delivery of a therapeutically
effective amount of the compound within the volume limitation of
the nasal cavity. Given the similarity in chemical structure
between compound I and verapamil, gallopamil, and devapamil, as
well as enantiomers and racemates thereof, those compounds are
expected to be similarly soluble under the conditions described
herein.
[0067] A common method of measuring the effectiveness of a
therapeutic agent in terminating an episode of a cardiac
arrhythmia, such as PSVT, is by analysis of an electrocardiogram
(ECG) recorded from a patient experiencing such an episode. The
pattern of an ECG describes the magnitude and timing of electrical
signaling within the cardiac tissue, and patients suffering from an
episode of PSVT typically exhibit a deviant ECG profile that is
consistent with the aberrant signaling in the heart. One of the key
features of healthy cardiac signaling is a temporal delay between
the initiation of atrial and ventricular action potentials. A delay
between signaling in the atria and ventricles is necessary for
efficient pumping of blood. Signaling in the atria must proceed
first, such that all blood in the atrial chambers is expelled into
the ventricles before the ventricles contract. This delay is
captured graphically on an ECG as the PR segment, which is the
interval between the beginning of a P wave (corresponding to the
onset of atrial depolarization) and the QRS complex (corresponding
to the onset of ventricular depolarization). Patients suffering
from an episode of PSVT typically experience a reduced delay due to
aberrant cardiac signaling that causes the cardiomyocyte tissue to
contract irregularly (Basta, et al., Cardiol. Clinics, 1997,
587-598). As such, these patients exhibit a reduced PR segment when
monitored by ECG analysis.
[0068] It has been shown that an increase of at least 10% in the PR
segment of an ECG recorded from a patient suffering from a cardiac
arrhythmia correlates well with a termination of the PSVT episode.
For instance, a therapeutic dose of verapamil administered
intravenously to patients suffering from an episode of PSVT has
been shown to induce a PR prolongation of at least 10%, which was
correlated with an efficacy of 85-90% for terminating the PSVT
episode (Reiter, et al., Clin. Pharmacol. Ther., 1982, 711-720). It
has also been shown that intravenous administration of tecadenoson
is capable of inducing PSVT termination with an efficacy of
approximately 86% (32 out of 37 patients treated experienced relief
from an episode of PSVT). This result was correlated with an
average PR prolongation of 8.5%. Collectively, these data indicate
that a therapeutic agent capable of inducing a PR prolongation of
at least about 10% would be expected to be effective in terminating
an episode of PSVT in a patient. Experiments have been performed in
which solutions of the invention containing the dissolved acetate
salt of compound I were nasally administered to patients suffering
from an episode of PSVT. The solutions that were administered to
patients contained varying concentrations of the acetate salt of
compound I. During the study, a solution containing a particular
concentration of the acetate salt of compound I was administered to
a patient experiencing an episode of PSVT, and the patient was
monitored by electrocardiography throughout the duration of the
experiment. Administration of solutions of the acetate salt of
compound I containing 60 mg or greater of compound i were capable
of inducing a median PR prolongation of greater than 10% in
patients experiencing a PSVT episode. The results of these
experiments demonstrate that a dosage containing 60 mg of compound
I contains an amount of compound I that is therapeutically
effective in terminating an episode of PSVT. Other preferable doses
of a compound described herein, such as compound I, verapamil,
gallopamil, or devapamil, include doses that range from 15 mg to
140 mg of the active compound (e.g., 15 mg, 20 mg, 25 mg, 30 mg, 35
mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg,
85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125
mg, 130 mg, 135 mg, 140 mg, etc.)
[0069] An aqueous solution containing the acetate or
methanesulfonate salt of a compound described herein, such as
compound I, verapamil, gallopanil, or devapamil, exhibit a
particular viscosity range. In certain embodiments, the viscosity
of such a solution can range from 10 mPa*s to 70 mPa*s (e.g., 10
mPa*s, 15 mPa*s, 20 mPa*s, 25 mPa*s, 30 mPa*s, 35 mPa*s, 40 mPa*s,
45 mPa*s, 50 mPa*s, 55 mPa*s, 60 mPa*s, 65 mPa*s, or 70 mPa*s). For
example, a solution containing a salt of compound 1 at a
concentration of 315 mg/mL exhibited a viscosity of between about
16.515 mPa*s to about 37.505 mPa*s. In another example, a solution
containing a salt of compound I at a concentration of 360 mg/mL
exhibited a viscosity of between about 25.645 mPa*S to about 63.105
mPa*s.
Permeation Enhancer
[0070] In order to exhibit an ideal pharmacokinetic profile, a
pharmaceutically active compound or pharmaceutically acceptable
salt thereof may be formulated with a material capable of enhancing
the permeability of the active agent. In the formulation of the
present invention, a compound described herein, such as compound 1,
verapamil, gallopamil, or devapamil, will ideally enter the
bloodstream rapidly (e.g., within 3 to 5 minutes of administration
to a patient).
[0071] In a preferred embodiment of the present invention, the
permeation enhancer of the instant formulation is a chelating
agent. More preferably, the chelating agent is capable of
coordinating divalent calcium ions (Ca). It has been shown that the
epithelial cells of mucous membranes are held in close contact by
the formation of tight junctions. The paracellular transport of a
pharmaceutically active compound through the epithelium requires
that the compound penetrate these intercellular junctions.
Transcellular transport, the alternative to paracellular transport,
requires that a compound penetrate the epithelium by traversing the
apical and basolateral membranes, a process for which many
molecules am not well-suited due to their large molecular volumes.
Chelating agents render paracellular transport possible, however,
by binding and sequestering intracellular calcium (Cassidy, et al.,
J Cell Biol., 1967, 32:685-698). Calcium is essential to the
biogenesis of tight junctions between epithelial cells, and the
reduction of intracellular calcium compromises the integrity of
these junctions and enables certain molecules to penetrate the
intercellular volume between neighboring cells.
[0072] Exemplary chelating agents capable of coordinating calcium
ions include aminopolycarboxylic acids. These include, without
limitation, iminodiacetic acid (IDA), nitrilotriacetic acid (NTA),
pentetic acid (DTPA), ethylenediaminetetracetic acid (EDTA),
ethylene glycol tetraacetic acid (EGTA),
(1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) (BAPTA),
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
and
N--(N-(3-amino-3-carboxypropyl)-3-amino-3-carboxypropyl)azetidine-2-carbo-
xylic acid (nicotianamine), among others. In a preferred
embodiment, the chelating agent is EDTA.
[0073] Despite the use of chelating agents such as EDTA to increase
the permeation capacity of drugs through epithelial tissue, it was
nonetheless surprising that the use of EDTA in the instant
formulation increased the permeation of compound I through the
nasal epithelium. The nasal vestibule, which accounts for
approximately 3-4% of the surface area of the nasal cavity, lacks
tight junctions altogether and is thus not affected by calcium
chelating agents. EDTA has been shown to modulate tight junction
formation, but even when junctions are compromised, the
intercellular pores in the nasal epithelium are particularly small.
As such, it has been postulated that the nasal epithelium is not
susceptible to permeability modulation by EDTA (Aungst, et al.,
Pharma. Res., 1998, 5:305-308). Additionally, the ability of EDTA
to increase permeation of a compound through the nasal epithelium
is attenuated as the molecular weight of the compound increases
(Nakanishi, et al., Chem. Pharm. Bull., 1984, 32:1628-1632).
pH Adjusting Agents
[0074] In certain embodiments of the invention, it is desirable to
adjust the pH of the aqueous solution including a pharmaceutically
acceptable salt of a compound described herein, such as compound I,
verapamil, gallopamil, or devapamil. The pH of the formulation can
be adjusted by treating the aqueous solution including a salt of
one of these compounds with a solution including an acidic or a
basic reagent. In preferred embodiments, the pH of the formulation
is adjusted by titration of the aqueous solution with a solution
including an acid. The pH of the formulation is desirably between
3.5 and 5.5, (e.g., 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3,
4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, or 5.5), and
is most desirably 4.5. The pH of the formulation can be adjusted by
adding an aqueous solution containing an acid to the formulation so
as to lower the pH to an ideal value. Exemplary acids that can be
used to titrate an aqueous solution containing a salt of a compound
described herein, such as compound I, verapamil, gallopamil, or
devapamil, include, without limitation, acetic acid, sulfuric acid,
and methanesulfonic acid. In preferred embodiments, the acid used
to adjust the pH of the formulation is sulfuric acid or
methanesulfonic acid.
Additional Excipients
[0075] Formulations of the instant invention may include other
agents capable of increasing the permeation, solubility, stability,
or efficacy of a compound described herein, such as compound I.
verapamil, gallopamil, or devapamil. Pharmaceutically acceptable
excipients may include antiadherents, antioxidants, binders,
coatings, compression aids, disintegrants, dyes (colors),
emollients, emulsifiers, fillers (diluents), film formers or
coatings, flavors, fragrances, glidants (flow enhancers),
lubricants, preservatives, printing inks, sorbents, suspensing or
dispersing agents, sweeteners, or waters of hydration. Exemplary
excipients include, but are not limited to: butylated
hydroxytoluene (BHT), calcium carbonate, calcium phosphate
(dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl
pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose,
gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose,
lactose, magnesium stearate, maltitol, mannitol, methionine,
methylcellulose, methyl paraben, microcrystalline cellulose,
polyethylene glycol, polyvinyl pyrrolidone, povidone,
pregelatinized starch, propyl paraben, retinyl palmitate, shellac,
silicon dioxide, sodium carboxymethyl cellulose, sodium citrate,
sodium starch glycolate, sorbitol, starch (corn), stearic acid,
stearic acid, sucrose, tale, titanium dioxide, vitamin A, vitamin
E, vitamin C, and xylitol. Additional excipients may include,
without limitation, polysorbate, propylene glycol, hydroxypropyl
.beta.-cyclodextrin, triethylcitrate, benzalkonium chloride, and
N-dodecyl-.beta.-D-maltoside.
[0076] The formulation of the present invention may optionally
include a pharmaceutically acceptable carrier. Examples of a
pharmaceutically acceptable carrier include, without limitation, a
preservative, antioxidant, fragrance, emulsifier, dye, or excipient
known or used in the field of drug formulation and that does not
significantly interfere with the therapeutic effectiveness of the
biological activity of the active agent, and that is non-toxic to
the patient.
Nasal Delivery System
[0077] The present invention additionally provides a nasal delivery
system for the administration of aqueous solutions of salts of a
compound described herein, such as compound I, verapamil,
gallopamil, or devapamil, to the nasal cavity of a patient
suffering from cardiac arrhythmia, stable angina, or migraine. The
nasal delivery system of the invention includes an aqueous solution
of the acetate or methanesulfonate salt of a compound described
herein, such as compound 1, verapamil, gallopamil, or devapamil, in
a unit dosage form. This solution may additionally contain other
materials, including, without limitation, a permeation enhancer,
pharmaceutically acceptable excipient, and/or a pH adjusting agent.
The nasal delivery system includes the unit dosage form as a pump
spray dosage. In this way, the nasal delivery system can be used to
administer an aqueous solution containing the acetate or
methanesulfonate salt of a compound described herein, such as
compound I, verapamil, gallopamil, or devapamil, into the nasal
cavity of a patient during an episode of cardiac arrhythmia, stable
angina, or migraine. At the onset of an episode, a patient can
easily self-administer this formulation containing one of these
active compounds by inserting the applicator of the nasal delivery
system into the nasal cavity and applying compressible pressure to
the pump of the system. This will trigger the release of a spray
including the aqueous solution of a salt of the active compound
into the nasal cavity and onto the nasal epithelium.
[0078] The nasal delivery system is analogous to nasal delivery
systems that are commercially available, such as those used to
deliver such drugs as Imitrex.RTM. (sumatriptan), sold by
GlaxoSmithKline (Brentford, UK) and Zomig.RTM. (zolmitriptan), sold
by Impax Pharmaceuticals (Hayward, Calif., USA). These systems
include a vial, a piston, a swirl chamber, and an actuator. Upon
applying pressure to the actuator, the liquid is forced through the
swirl chamber and released as a spray. These nasal delivery systems
often include a pressure point mechanism to ensure that a
reproducible pressure is applied to the system in order to achieve
release of a consistent volume of spray (Rapoport, et al.,
Headache, 2006, 46:S192-S201). The nasal delivery system of the
invention includes a unit dosage form that contains no more than
four (e.g., one, two, three, or four single pump spray dosages. In
alternative embodiments, the unit dosage form includes no more than
two (e.g., one or two) single pump spray dosages. The unit dosage
form can be configured for delivery of no more than 200 .mu.L
(e.g., 200 .mu.L 190 .mu.L, 180 .mu.L, 170 .mu.L, 160 .mu.L, 150
.mu.L, 140 .mu.L, 130 .mu.L, 120 .mu.L, 110 .mu.L, or 100 .mu.L) of
the aqueous solution including a salt of a compound described
herein, such as compound I, verapamil, gallopamil, or devapamil. In
alternative embodiments, the unit dosage form is configured for
delivery of no more than 150 .mu.L (e.g., 150 .mu.L, 140 .mu.L, 130
.mu.L, 120 .mu.L, 110 .mu.L, or 100 .mu.L) of the aqueous solution
including the acetate or methanesulfonate salt of a compound
described herein, such as compound I, verapamil, gallopamil, or
devapamil.
Methods of Formulation
[0079] The present invention additionally provides methods of
making an aqueous solution including a salt of a compound described
herein, such as compound I, verapamil, gallopamil, a devapamil. In
certain embodiments of the invention, the free base of one of these
compounds is treated with a solution including a first dissolved
acid. The resulting mixture contains the acid addition salt
including the protonated aminium form of the compound and the
conjugate base of the first dissolved acid. Examples of the first
dissolved acid that are suitable for formation of the salt of the
active compound include acetic acid and methanesulfonic acid. EDTA
may be added to this solution. The first dissolved acid may be
added to the compound so as to form a salt containing the compound
and between 0.5 and 1.5 molar equivalents of the acid. For example,
the compound may be treated with acetic acid in order to form a
salt containing the compound and between 0.5 and 1.5 molar
equivalents of acetic acid relative to the compound. Alternatively,
the compound may be treated with methanesulfonic acid in order to
form a salt containing the compound and between 0.5 and 1.5
equivalents of methanesulfonic acid relative to the compound. In
particular embodiments, the mixture containing the salt is heated
and mechanically stirred until the compound has fully dispersed
within the mixture. In additional embodiments, the pH of the
mixture is then adjusted by adding a solution including second
dissolved acid to this mixture. Examples of the second dissolved
acid useful for adjusting the pH of the formulation include acetic
acid, sulfuric acid, and methanesulfonic acid. In preferred
embodiments, the second dissolved acid is sulfuric acid. In
particular embodiments, the solution is subsequently diluted such
that the final concentration of the compound in the mixture is at
least 300 mg per 1 milliliter (e.g., 300 mg/mL, 310 mg/mL, 320
mg/mL, 330 mg/mL, 340 mg/mL, 350 mg/mL, 360 mg/mL, 370 mg/mL, 380
mg/mL, 390 mg/mL, 400 mg/mL, 410 mg/mL, 420 mg/mL, 430 mg/mL, 440
mg/mL, 450 mg/mL, 460 mg/mL, 470 mg/mL, 480 mg/mL, 490 mg/mL, 500
mg/mL, 510 mg/mL, 520 mg/mL, 530 mg/mL, 540 mg/mL, 550 mg/mL, 560
mg/mL, 570 mg/mL, 580 mg/mL, 590 mg/mL, 600 mg/mL, etc).
[0080] The acetate and methanesulfonate salts of a compound
described herein, such as compound I, verapamil, gallopamil, or
devapamil, can exhibit very high solubility in aqueous solution. An
aqueous solution containing one of these salts can remain
homogeneous for extended periods of time, even at high
concentrations and at reduced temperatures. For example, highly
concentrated solutions containing compound I and between 0.5 and
1.5 molar equivalents of acetic acid or methanesulfonic acid
relative to the compound remain homogeneous at room temperature
with no observable precipitation. In certain embodiments, these
solutions remain homogeneous at 10.degree. C. for at least 4 days,
and in alternative embodiments these solutions are remain
homogeneous at 2-5.degree. C. for at least 7 days. For example, an
aqueous solution containing 300 mg/mL of compound 1, one molar
equivalent of methanesulfonic acid 10 mM sodium acetate, and 5 mM
disodium EDTA, adjusted to a pH of 4.5 with methanesulfonic acid,
remains homogeneous at room temperature and at 2-5.degree. C.
without any observable precipitation. Moreover, this solution
remains homogeneous even at 0.degree. C. for at least 7 days.
Additionally, an aqueous solution containing 400 mg/mL of compound
I, one molar equivalent of methanesulfonic acid relative to
compound I, 10 mM sodium acetate, and 5 mM disodium EDTA, adjusted
to a pH of 4.5 with methanesulfonic acid also remains homogeneous
at room temperature, 2-5.degree. C. and remains homogeneous at
0.degree. C. for at least 7 days. In another example, a solution
containing 350 mg/mL of compound I and one molar equivalent of
acetic acid relative to compound I, adjusted to a pH of 4.5 with
3.6 M sulfuric acid remains homogeneous at room temperature and
also remains homogeneous at 10.degree. C. for at least 3 days.
Additionally, a solution containing over 500 mg/mL of compound I
and one molar equivalent of acetic acid relative to compound I,
adjusted to a pH of 4.5 with 3.6 M sulfuric acid remains
homogeneous at room temperature.
[0081] In order that this invention be more fully understood, the
following examples are set forth. These examples are for the
purpose of illustration only and are not to be construed as
limiting the scope of the invention in any way.
EXAMPLES
Example 1: Synthesis methyl
3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)-
benzoate
Part I: Synthesis of
5-Bromo-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
##STR00014##
[0083] Method A, Step 1:
[0084] To a solution of 9.99 g (56.4 mmol) of
(3,4-Dimethoxyphenyl)acetonitrile in 141 mL of tetrahydrofuran
(THF) at -30.degree. C., was slowly added 56.4 mL (56.4 mmol) of
sodium bis(trimethylsilyl)amide (NaHMDS, 1.0 M in THF). The mixture
was stirred at -30.degree. C. for 10 minutes and 10.6 mL (113.0
mmol) of 2-bromopropane was added. The mixture was heated to reflux
for 2 hours (h) then left at 22.degree. C. for about 16 h. A
saturated aqueous solution of NH.sub.4Cl was added and the mixture
was extracted with ethyl acetate. The organic layer was washed with
brine, dried (Na.sub.2SO.sub.4), filtered and evaporated. The
residue was purified by flash chromatography on silica gel eluting
first with hexane and then gradually increasing to 15% ethyl
acetate/hexane to give
2-(3,4-dimethoxyphenyl)-3-methylbutanenitrile as an oil.
[0085] Method A, Step 2:
[0086] To a solution of 11.21 g (51.1 mmol) of
2-(3,4-dimethoxyphenyl)-3-methylbutanenitrile in 126 mL of
tetrahydrofuran (THF) at -30.degree. C., was slowly added 46.0 mL
(46.0 mmol) of sodium bis(trimethylsilyl)amide (NaHMDS, 1.0 M in
THF). The mixture was stirred at -30.degree. C. for 10 minutes and
9.40 mL (256 mmol) of 1,3-dibromopropane was added dropwise. The
mixture was warmed to 22.degree. C. and stirred for about 16 h. A
saturated aqueous solution of NH.sub.4Cl was then added and the
mixture was extracted with ethyl acetate. The organic layer was
washed with brine, dried (Na.sub.2SO.sub.4), filtered and
evaporated. The residue was purified by flash chromatography on
silica gel eluting first with hexane and then gradually increasing
to 15% ethyl acetate/hexane to give
5-bromo-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile as an
oil.
Part II: Synthesis or methyl 3-(2-(methylamino)ethyl)benzoate
##STR00015##
[0088] To a solution of 5.71 g (24.9 mmol) of methyl
3-bromomethylbenzoate in 36 mL of methanol was added 2.11 g (32.4
mmol) of potassium cyanide. The mixture was refluxed for about 16
h, cooled to 22.degree. C. and filtered. The filtrate was
evaporated and the residue was purified by flash chromatography on
silica gel, eluting first with hexane and then gradually increasing
to 15% ethyl acetate/hexane to give methyl
3-(cyanomethyl)benzoate.
[0089] To a solution of 1.31 g (7.48 mmol) of methyl
3-(cyanomethyl)benzoate in 31 mL of THF stirred at -10.degree. C.
was slowly added 710 mg (18.7 mmol) of sodium borohydride followed
by 1.44 mL (18.7 mmol) of trifluoroacetic acid. The mixture was
warmed to 22.degree. C. and stirred for about 16 h. About 100 mL of
water was carefully added to the mixture (gas evolution). The
mixture was extracted with ethyl acetate (5.times.50 mL). The
organic phase was washed with brine, dried (Na.sub.2SO.sub.4),
filtered and evaporated to give methyl 3-(2-aminoethyl)benzoate
which was used in the next step without purification.
[0090] Method B:
[0091] To 5.12 g (28.6 mmol) of methyl 3-(2-aminoethyl)benzoate in
71 mL tetrahydrofuran (THF) was added 7.48 g (34.3 mmol) of
BOC.sub.2O. The mixture was stirred for about 16 h at 22.degree. C.
and 100 mL of water was added. The mixture was extracted with ethyl
acetate (2.times.100 mL) and the organic phase was washed with
brine, dried (Na.sub.2SO.sub.4) and evaporated. The residue was
purified by flash chromatography on silica gel, eluting first with
hexane and then gradually increasing to 20% ethyl acetate/hexane to
give methyl 3-(2-(tert-butoxycarbonylamino)ethyl)benzoate which was
further converted to III by Method C (described below).
[0092] Method C, Step 1:
[0093] To a solution of methyl
3-(2-(tert-butoxycarbonylamino)ethyl)benzoate in dry THF under a
nitrogen atmosphere was added dropwise NaHMDS (1.0 M in THF) at
0.degree. C. After stirring for 10 min, dimethyl sulfate was added
and the reaction was warmed to 22.degree. C. and stirred for about
16 h. The reaction was quenched by adding 25 mL of saturated
NaHCO.sub.3 and the mixture was extracted with DCM (2.times.25 mL).
The combined organic extracts were dried (Na.sub.2SO.sub.4) and
evaporated and the residue was purified by flash chromatography on
silica gel, eluting first with hexane and then gradually increasing
to 10% ethyl acetate/hexane to give methyl
3-(2-(tert-butoxycarbonyl(methy)amino) ethyl)benzoate.
[0094] Method C, Step 2:
[0095] To a solution of methyl
3-(2-(tert-butoxycarbonyl(methyl)amino) ethyl)benzoate in DCM at
0.degree. C. was added trifluoroacetic acid (TFA). The reaction was
warmed to 22.degree. C., stirred for 3 h and the solvents were then
evaporated. The residue was partitioned between 100 mL of ethyl
acetate and 100 mL of 1 N NaOH which had been saturated with NaCl.
The aqueous layer was back-extracted with ethyl acetate (6.times.50
ml) and the combined organics were dried (Na.sub.2SO.sub.4) and
evaporated to give 2c as a colorless oil.
Part II: Reaction of Compound II with Compound II Produced Compound
I
[0096] Analysis of the product by mass spectrometry revealed a peak
with a mass-to-charge ratio (m/z) of 453, corresponding to the M+H
molecular ion of compound I.
Example 2: Concentrated Solution of Acetate Salt of Compound I
[0097] A concentrated aqueous solution of the acetate salt of
compound I is formed according to the following protocol:
[0098] An aqueous solution of 7.5 M sulfuric acid is first made by
diluting concentrated sulfuric acid in water and manually mixing in
a sealed bottle, periodically venting the pressure by releasing the
bottle cap. Separately, 175.+-.1.0 g of compound I is dispensed
from a pre-hated container into a glass bottle and maintained at a
temperature of 50.+-.2.degree. C. in a water bath. Next,
96.7.+-.0.2 mL of a 4.0 M acetic acid solution is added to compound
I, followed by 83.3 mL.+-.0.2 mL of a 31.8 mM solution of EDTA. The
mixture containing the (-) enantiomer (S-enantiomer) of compound I
is maintained at 50.+-.2.degree. C. and stirred using a magnetic
stir bar during both additions. Heating and stirring is continued
until the compound appears to be fully dispersed throughout the
mixture.
[0099] Upon complete dispersion of compound I, the solution of 7.5
M sulfuric acid is added drop-wise to the compound I mixture until
a pH of 5.0.+-.0.1 is reached. At this point, heating is
discontinued and the mixture continues to stir. The mixture is then
allowed to cool to within 2.degree. C. of ambient temperature. A
solution of 0.9 M sulfuric acid is then added drop-wise to the
mixture until a pH of 4.5.+-.0.1 is reached. The mixture containing
compound I is then diluted to 90% of the final target volume by the
addition of water to the mixture, and the pH is monitored after
this dilution. If necessary, the pH is lowered back to 4.5.+-.0.1
by drop-wise addition of 0.9 M sulfuric acid. The mixture is then
diluted to the final target volume by the addition of water.
[0100] This protocol readily can be adapted to provide a
concentrated solution of the methanesulfonate salt of compound
I.
Example 3: Nasal Administration of Compound I
[0101] A patient experiencing an episode of PSVT can use a nasal
delivery system containing the acetate or methanesulfonate salt of
compound I in order to nasally self-administer a therapeutically
effective amount of compound I and alleviate the symptoms of this
episode. At the onset of an episode of PSVT, a patient can hold the
nasal delivery system up to the nose, such that the applicator of
the system is inserted into the nasal cavity. The nasal delivery
system is typically held between the second and third fingers, and
the patient's thumb is placed on the actuator. This process is
similar to the use of commercially available nasal delivery systems
such as those used to deliver such drugs as Imitrex.RTM.
(sumatriptan), sold by GlaxoSmithKline (Brentford, UK) and
Zomig.RTM. (zolmitriptan), sold by Impax Pharmaceuticals (Hayward,
Calif., USA). The patient can then apply pressure to the actuator,
which forces the liquid solution containing the dissolved acetate
or methanesulfonate salt of compound I through a swirl chamber,
causing the solution to be released from the tip of the applicator
as a spray. The solution may be administered as one, two, three, or
four single pump spray dosages in order to deliver 60 mg or more of
compound I to the nasal epithelium.
[0102] The spray administered as described delivers the solution
containing the acetate or methanesulfonate salt of compound I to
the nasal epithelium, allowing compound I to be penetrate the
epithelium and rapidly enter the bloodstream. The acetate or
methanesulfonate salt of compound I administered in this way
reaches a maximum concentration in plasma within 3 to 5 minutes
after administration to the patient, and minimal concentrations of
the compound in plasma are observed within 50 to 60 minutes of
administration. In this manner, the patient experiences relief from
an episode of PSVT very soon after administration, and because of
the ideal pharmacokinetic profile of compound I, the drug does not
persist in the bloodstream long enough to induce adverse side
effects.
OTHER EMBODIMENTS
[0103] While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications and this application is intended
to cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the present disclosure come within
known or customary practice within the art to which the invention
pertains and may be applied to the essential features hereinbefore
set forth.
[0104] All references, patents, patent application publications,
and patent applications cited herein are hereby incorporated by
reference to the same extent as if each of these references,
patents, patent application publications, and patent applications
were separately incorporated by reference herein.
* * * * *